BELITE BIO INC - ADR (BLTE) Stock News
NASDAQ:BLTE - Nasdaq - US07782B1044 - ADR - Currency: USD
BLTE Latest News, Press Relases and Analysis
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
- 500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July ...
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profileTrial...
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Belite Bio Announces Registered Direct Offering of $15 Million
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (
Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of...
Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Belite Bio to Participate in Four Upcoming Investor Conferences
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on...
Belite Bio to Participate in Four Upcoming Investor Conferences
UPDATE - International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025
Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on...
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development...
Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent...
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on...
Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
Belite Bio to Participate in the Leerink Partners Global Healthcare Conference
Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects
An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the...
Belite Bio Announces Registered Direct Offering of $15 Million
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of...
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on...